Maccura Biotechnology Co. Ltd. (300463.SZ) engages in the research, development, manufacture, and sale of in vitro diagnostic (IVD) products and related services for medical laboratories primarily in China with international operations. Founded in 1994 and headquartered in Chengdu, China, the company offers a comprehensive portfolio of core products including chemiluminescence immunoassay analyzers and reagents; clinical chemistry reagents and systems for hepatic, renal, cardiac, lipid, coagulation, and special protein testing; automatic hematology analyzers and workstations; molecular diagnostics such as real-time fluorescence quantitative PCR kits, digital PCR systems, and nucleic acid extraction systems; urinalysis analyzers; hemostasis and coagulation analyzers; glycohemoglobin and specific proteins analyzers; biochemistry systems; point-of-care testing (POCT) devices like fluorescence immunoassay analyzers and colloidal gold kits; pathology products; blood transfusion reagents; and SARS-CoV-2 detection kits. Recent developments include the launch of a new Chlamydia pneumoniae IgG antibody detection kit with product registration certification; advancement of the Tianfu International Bio-City IVD Industrial Park project into validation, debugging, and calibration stages; a new product launch contributing an estimated ¥150 million in revenue in 2022; international market expansion into Europe, Southeast Asia, and the US reagents market; and ongoing strategic partnerships to enhance distribution and integrate AI into diagnostics.